LKT Labs

Biochemicals for Life Science Research

Linagliptin

Linagliptin

Product ID L337521
Cas No. 668270-12-0
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $45.00 In stock
10 mg $60.00 In stock
25 mg $105.00 In stock
50 mg $180.00 In stock
Bulk Quote

Quicklinks

Description

Linagliptin is a dipeptidyl peptidase 4 inhibitor glucose-lowering compound with low risk of inducing hypoglycaemia. It has been found that linagliptin may modify several measures of microvascular function including hyperaemia area, resting blood flow, and peak blood flow in the fasting state. Treatment of STZ-diabetic Wistar rats was shown to decreases levels of oxidative stress, protect against microvascular damage, enhance neuronal cell survival, and prevent vasoregression.
Furthermore, treatment was found to decrease aortic pulse wave velocity, glycated haemoglobin, fasting plasma glucose, and triglycerides in people with early type 2 diabetes. Contrarily, linagliptin has also been known to cause adverse reactions such as ulcers and blisters.

Product Info

Cas No.

668270-12-0
Purity

≥98%
Formula

C25H28N8O2
Formula Wt.

472.55
Chemical Name

8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
IUPAC Name

8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butyn-1-yl)-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-3,7-dihydro-1H-purine-2,6-dione
Synonym

Tradjenta, BI 1356, Ondero
Solubility

Soluble in DMSO (17 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), ethanol (1 mg/ml at 25 °C), 0.5% hyroxyethylcellulose (30 mg/ml at 25 °C), and methanol.

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

L337521 MSDS PDF
Info Sheet

L337521 Info Sheet PDF

References

Jax T, Stirban A, Terjung A, et al. A randomized, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol. 2017 Jan 21;16(1):13. PMID: 28109295.

Dietrich N, Kolibabka M, Busch S, et al. The DPP4 inhibitor linagliptin protects from experimental diabetic retinopathy. PLoS One. 2016 Dec 12;11(12):e0167853. PMID: 27942008.

de Boer SA, Heerspink HJL, Juarez Orozco LE, et al. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: a randomized, double-blind, controlled 26-week trial (RELEASE). Diabetes Obes Metab. 2017 Aug;19(8):1147-1154. PMID: 28244635.

Psomadakis C, Shahzad N, Katz J. Linagliptin-associated blistering and ulceration. BMJ Case Rep. 2017 May 31;2017. PMID: 28566414.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C1867

    Ceramide

    Endogenous sphingosine-based lipid, component o...

    ≥98%
  • M9644

    Myelin Basic Protein (87-99), guinea pig/human

    Immunodominant peptide epitope occurring in mul...

    ≥95%
  • C0261

    Captopril

    ACE inhibitor.

    ≥98%
  • F4480

    5-Fluorouracil

    Pyrimidine analog; inhibits thymidylate synthas...

    ≥98%
  • B3272

    Bis(3,5-dibromosalicyl) Fumarate

    Aspirin analog; hemoglobin chain cross-linker.<...

    ≥91%
  • F4482

    Fluvastatin Sodium

    Statin; HMG-CoA reductase inhibitor, potential ...

    ≥98%
  • T7676

    HT-2 Toxin

    Trichothecene mycotoxin produced by Fusarium.

    ≥98%, TLC, HPLC
  • U0618

    Ubenimex

    Dipeptide; aminopeptidase (N/CD13) inhibitor.

    ≥98%
  • G5216

    GNE-7915

    LRRK2 inhibitor.

    ≥98%
  • S7868

    SRT1720 Hydrochloride

    SIRT 1 activator, SIRT3 inhibitor.

    ≥98%
  • P014442

    Palbociclib

    CDK4/6 inhibitor.

    ≥98%
  • T1849

    Temozolomide

    Imidazotetrazine, DNA alkylator.

    ≥98%
  • O4672

    Olsalazine Sodium

    5-Aminosalicylate prodrug, NSAID; COX-1/2 inhib...

    ≥98%
  • T1006

    10-Acetoacetyl Paclitaxel

    Synthesis impurity

    ≥95%
  • D023721

    Dasatinib

    Multikinase inhibitor.

    ≥99%
  • I7447

    1-Isothiocyanato-6-(methylsulfenyl)-hexane

    Synthetic ITC, erucin analog.

    ≥98%
  • T5769

    Toremifene Base

    SERM, androgen modulator.

    ≥98%
  • E6994

    Erythromycin

    Macrolide; protein translation inhibitor, mamma...

    ≥94%
  • C3260

    Ciprofibrate

    Fibrate; PPARα agonist.

    ≥98%
  • E7857

    Etofenamate

    NSAID; COX-1/2 and lipoxygenase inhibitor.

    ≥98%